Dataset opportunity
Medasil — 监管记录数据集机会
Medasil 持有的中等规模监管记录数据集，可用于监管 RAG 和合规性 Copilots。
Score
69.1
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
收购
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球监管事务中的人工智能市场 = 2024 年为 13.1 亿美元，复合年增长率为 18.60%。
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
监管记录数据集
Modality
文本
Sector
医疗保健
Volume
中等
Freshness
定期
Rarity
高（专有）
Accessibility
部分
Legal
公司所有 — 可授权许可
Buyer persona
RegTech 和合规性 AI 供应商
Medasil 持有文本模态的监管记录数据集，包含其 NHS 供应链数十年的专有工业数据，如制造规范、质量控制记录和历史业务记录，可追溯至 1974 年。这些广泛的、真实的文本数据非常适合开发和微调监管 RAG 系统，使其能够准确回答有关医疗器械合规性和制造历史的复杂查询。
全球监管事务中的人工智能市场在 2024 年的估值为13.1 亿美元，预计将以18.60% 的复合年增长率增长，显示出巨大的商业价值。尽管由于其硅基设备的专有技术规范而存在访问复杂性，但该数据集的稀有性和深度为旨在自动化和加强高增长领域监管合规性的 AI 买家提供了显著的竞争优势。⚠ 尽职调查（有价值的数据，可协商的访问权限）：数据主要为工业制造和质量控制记录；自 1974 年以来 NHS 采购的历史供应链数据；硅基医疗器械的专有技术规范。· 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Medasil 拥有数十年来医疗器械制造的深入、专有的监管和商业记录档案。该数据集为RegTech 和合规性 AI 供应商提供了一个难得的机会，可以获取真实文档，包括与ISO13485 合规性和长期NHS 供应链相关的材料。在快速增长的监管事务中的人工智能市场中，这些数据对于构建和验证能够驾驭真实合规路径的复杂RAG 模型至关重要。
See dimension details ↓- Dataset Specificity78
主导的“监管”，医疗保健行业，2 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity70
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
定期
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
适用于监管 RAG
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
AI 买家需求源于在快速扩张的监管事务中的人工智能市场中自动化和加强合规性的迫切需求，该市场预计将以 **18.60% 的复合年增长率**增长。
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility50
受限/未知
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility44
低难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型，3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License92
所有权=公司所有，许可=干净
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 个数据需求信号（2 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus70
盈余=中等 — 超出已货币化的专有数据
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ 良好目标 — Medasil 是一个理想的目标，因为它是一家历史悠久、家族拥有的英国中小型企业，生产一次性医疗器械，这一过程本身就会产生其似乎未货币化的专有监管、质量和生产数据。
- Deep Qualification90
✓ 通过 — Medasil 是主要的数据持有者；作为自 1974 年以来一直生产受监管医疗器械的长期制造商，它本身就产生了机会中指定的精确专有制造、质量和供应链数据。
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Regulatory records
证据指向一个监管合规文本存储库，特别证明了对关键的ISO13485 医疗器械标准的遵守，这是服务于全球医疗保健行业的 AI 平台的关键培训数据。
Industrial data
这表明存在来自受控8 类洁净室环境的制造过程数据，为买家提供了一个独特的数据集来模拟生产条件与产品质量控制之间的联系。
business_records
持有者拥有数十年的商业文件，详细说明了与 NHS 的长期供应关系，为培训 AI 关于公共部门采购和医疗保健供应链物流的细微差别提供了宝贵的语料库。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Medasil Regulatory Records — a Moderate regulatory records dataset (Text modality) in the healthcare domain. Primary AI use-case: Regulatory RAG. Market signal: Global AI in Regulatory Affairs market = $1.31B in 2024, CAGR 18.60% (source: Grand View Research). Investment score 69.1/100 (confidence 0.49). Recommended action: Acquire.
From the marketplace
Explore live data opportunities
Smeag — 监管记录数据集机会
View opportunity →法律Deutsche Recycling — 监管记录数据集机会
View opportunity →医疗保健Meridian Medical — 监管记录数据集机会
View opportunity →